ZEISS Vision Care Posters

The development of a virtual control model for use in myopia control RCTs is needed. Using a vulnerable population as a non-treatment control is ethically questionable. The model presented here provides a valid alternative to a real-world control group for these RCTs of similar race, age, and gender distribution.

CARE lenses  significantly affect the myopia progression rate, irrespective of past progression or age. When compared to myopia progression in the year prior to the trial, progression during the  first year of the trial was much slower.

Subjective ratings indicate that children adapted to CARE lenses and after 3 months, ratings were no different to SVL for most aspects. There were no differences in central VA, but peripheral VA was reduced by approximately 1 line.

Considerable advances have been made in developing solutions to slow myopia and include specially designed spectacle lenses such as CARE. It is crucial to determine if these solutions can be applied broadly across populations. Our results indicate that CARE spectacles effectively slow myopia in both Asian and European children with myopia.

We demonstrate that efficacy if myopia control strategies including MyoCare is better explained using the absolute difference (in dioptres or mms) between test and control groups rather than using relative efficacy or percent values. Specifically, use of percent (relative or proportional effect) results in over estimation of efficacy for average progressors but underestimates slow as well as fast progressors.

In a 2-year trial assessing the efficacy of MyoCare in European children (CEME) study, 12 – month interim results indicate that MyoCare is able to significantly slow myopia. The children participating in the CEME study will continue to be monitored to provide a more comprehensive evaluation of MyoCare's long-term effectiveness in slowing down the progression of myopia.

Interim analysis with the next-generation myopia control spectacle lens with C.A.R.E. technology from the CEME study demonstrated to be efficient over six months. Children will continue to be monitored after one and two years of lens wear for a more comprehensive evaluation of the long-term efficacy of the C.A.R.E. spectacle lens in slowing the progression of myopia.

In children with myopia, after twelve months of lens wear, both ZEISS MyoCare and ZEISS MyoCare S were found to significantly slow myopia progression compared to single vision lenses.

Probability of surviving fast progression was greater with ZEISS MyoCare than single vision. Whilst 51% of single vision eyes experienced fast progression ( -0.75D or worse) in myopia after twelve months, only 17% of ZEISS MyoCare and 14% of ZEISS MyoCare S wearing eyes experienced fast progression.

Emmetropic Progression Ratio (EPR) demonstrates that ZEISS MyoCare and ZEISS MyoCare S reduced myopic axial length growth by an average of 70% and 68% compared to emmetropic eye growth. Seven of ten eyes wearing ZEISS MyoCare or ZEISS MyoCare S had eye growth similar to or equivalent to emmetropic eyes.

In children wearing single vision spectacle lenses, myopia progressed faster in those with parental myopia. In comparison, in children wearing spectacle lenses incorporating C.A.R.E., myopia progression was not significantly related to parental myopia.

High daily wear time was reported with myopic children wearing speacacle lenses incorporating cylindrical annular refractive elements (C.A.R.E.) and no wear time difference compared to single vision lenses. Subjective evaluation of vision for different distances and activities revealed high subjective acceptance, comparable to single vision lenses.